[INTERVIEW] Recce gearing up for Indonesian trials, page-47

BobF, don't forget about R435, which is a variant of R327 aimed specifically at oral administration.

Source: https://finance.yahoo.com/news/recce-pharmaceuticals-announces-positive-oral-120000992.html

So, over four years ago, they split off oral dosage into a different development path, so that it will not interrupt development of the flagship product R327, which is aimed at IV administration targeting sepsis in the blood. That is it's primary goal.

They also created R529, for the same purpose; to not hold up development of R327, yet allow for specifically targeting viral infections.

Both variants as far as I understand, take a much lower priority to R327 and quite rightly so.